Pharma BD Deal Intelligence
Novo Nordisk paid $1.35B for Emisphere's oral peptide delivery technology—the platform that made Rybelsus possible as the first oral GLP-1 receptor agonist. The deal solved a decades-old pharmaceutical challenge: delivering a peptide drug in pill form for the diabetes market.
Novo Nordisk acquired Emisphere for $1.35B for pill-based diabetes treatment.
Novo Nordisk completes acquisition of Emisphere Technologies for $1.35 billion ($7.83/share); separately completed $450M acquisition of the Eligen…
Novo Nordisk FY2024: Rybelsus (oral semaglutide, built on Emisphere's Eligen/SNAC delivery technology) net sales of DKK 23.3 billion (~$3.4B).
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Novo Nordisk acquired Emisphere Technologies (Nasdaq: EMIS) for $1.35 billion in cash (~$7.83/share on ~170.9M fully diluted shares; ~17% premium), completing December 8, 2020. Concurrently, Novo Nordisk paid a separate $450 million to affiliates of MHR Fund Management LLC to acquire the related Eligen/SNAC royalty-stream obligations — bringing total consideration to roughly $1.8 billion. The prize was Emisphere's proprietary Eligen oral drug-delivery technology (the SNAC absorption-enhancing carrier), already licensed by Novo Nordisk and used in the oral formulation of semaglutide (Rybelsus), the first oral GLP-1 receptor agonist. The buy-in eliminated future royalty leakage on a franchise whose oral semaglutide product reached DKK 23.3 billion (~$3.4B) in net sales by FY2024.
$53.5B Global GLP-1 Market (2024)
Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance combined with progressive beta-cell dysfunction, leading to hyperglycemia. It affects approximately 38 million U.S. adults, with an additional ~98 million having prediabetes. Obesity — a complex chronic disease in which excess adiposity increases health risk, commonly defined by BMI ≥30 kg/m^2 — affects more than 100 million U.S. adults and is the dominant modifiable driver of T2D incidence. Shared risk factors include age, family history, ancestry, sedentary lifestyle, energy-dense diets, and gestational diabetes history. T2D is diagnosed by fasting plasma glucose ≥126 mg/dL, HbA1c ≥6.5%, 2-hour OGTT ≥200 mg/dL, or symptomatic hyperglycemia with random glucose ≥200 mg/dL. Complications span microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (coronary disease, stroke, peripheral arterial disease) domains, plus MASLD/MASH and increased cancer risk. Management is individualized and combines medical nutrition therapy, physical activity, and weight management (including intensive lifestyle intervention, pharmacotherapy, and metabolic/bariatric surgery in eligible patients) with pharmacologic therapy — metformin, GLP-1 receptor agonists, GIP/GLP-1 co-agonists, SGLT2 inhibitors, DPP-4 inhibitors, thiazolidinediones, sulfonylureas, and insulin — with emphasis on cardiorenal risk reduction using agents with proven outcomes benefit.
SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) is the key technology enabling oral peptide delivery. It temporarily disrupts gastric epithelium to allow semaglutide absorption. Rybelsus ($2.5B) provides an oral alternative to injectable Ozempic. Oral semaglutide has since been approved for CV risk reduction and is being developed for obesity (oral Wegovy).
Novo Nordisk completed $1.35B acquisition of Emisphere Technologies, gaining Eligen oral delivery technology (SNAC) used in Rybelsus.
Rybelsus using Emisphere's SNAC technology exceeded $2B annually, validating oral delivery platform's importance to Novo's GLP-1 franchise.
SNAC technology enabled first oral GLP-1 (Rybelsus) at $2B+ annually. $1.35B secured critical technology underpinning Novo's oral semaglutide franchise.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Emisphere Technologies (this deal) | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 58 |
← Browse all deals · How we score deals
More: 2020 deals · Novo Nordisk A/S deals · Metabolic deals